Benign Prostatic Hyperplasia Drugs Market Analysis & Forecast 2024-2030

Global Benign Prostatic Hyperplasia Drugs Market is expected to reach USD 25828.10 million by 2030 with CAGR of 8.4% between 2024 and 2030

Benign Prostatic Hyperplasia Drugs are the medical Drugs used for the treatment of Benign Prostatic Hyperplasia. Benign prostatic Hyperplasia is the nonmalignant enlargement of the prostate gland. It refers to stromal and glandular epithelial hyperplasia that occurs in the periurethral transition zone of the prostate that surrounds the urethra. Benign Prostatic Hyperplasia clinically manifest as lower urinary tract symptoms consisting of irritative (urgency, frequency, nocturia) and obstructive symptoms (hesitancy, a weak and interrupted urinary stream).  

Prolonged obstructions may eventually lead to acute urinary retention, recurrent urinary tract infection, hematuria bladder calculi, and renal insufficiency). The intake of the Benign Prostatic Hyperplasia Drugs reduces the prostate DTH level thus resulting in decreased prostate volume or size and improved urinary flow rate. The consumption of Benign Prostatic Hyperplasia Drugs heals the symptoms of Benign Prostatic Hyperplasia such as relief obstruction, improve bladder emptying, prevent UTIs, and avoid renal insult.  

The Benign Prostatic Hyperplasia Drugs market is expected to make a significant growth in the forecasted period. The major factor of the growth of the Benign Prostatic Hyperplasia Drugs market is increase in male geriatric population. The rising awareness about prostate cancer and other urological disorders are also increasing the demand for the Benign Prostatic Hyperplasia Drugs. The Benign Prostatic Hyperplasia is becoming the common conditions in aging men which is increasing the demand for the Benign Prostatic Hyperplasia Drugs. The other major factor of growth in Benign Prostatic Hyperplasia is increase in population.  

As the population is increasing, the patients of Benign Prostatic Hyperplasia are increasing, which is increasing the demand for Benign Prostatic Hyperplasia Drugs. Rising awareness about the Benign Prostatic Hyperplasia Drugs will act as another driving factor to the market. However, inclination of patients toward minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT) is hampering the market growth.  

The study covers a detailed analysis, growth and forecast of the Benign Prostatic Hyperplasia Drugs Market. The report includes market analysis on global and regional level. The study covers historical data analysis from 2018 to 2023 and market forecast for 2024 to 2030 based on revenue generated. The study includes market value in terms of revenue in million USD for years 2018-2030 and compound annual growth rate (CAGR) in % from 2024 to 2030. The market is expected to show constant growth between 2024 to 2030.  

The report comprises value chain analysis for each of the product segments. Value chain analysis offers in-depth information about value addition at each stage. The study includes drivers and restraints for Benign Prostatic Hyperplasia Drugs Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting the growth of the market. Research report includes major player analysis with shares of each player inside market, growth rate and market attractiveness in different end-users/regions. Our study Benign Prostatic Hyperplasia Drugs Market helps users to make precise decision to expand their market presence and increase market share.  

The report provides Benign Prostatic Hyperplasia Drugs Market Dynamics, includes industry growth drivers, challenges, opportunities, risk, constraints as well as threats. Report also includes Manufacturing Cost Analysis mainly included Raw Materials Analysis, Price Trend of product, Mergers & Acquisitions, Expansion, Key Suppliers of product, Concentration Rate of Benign Prostatic Hyperplasia Drugs Market, Manufacturing Process Analysis. Research Report contains Market Effect Factors analysis mainly included Technology Progress, Consumer Needs Trend, External Environmental Change.  

Global Benign Prostatic Hyperplasia Drugs Market: Product Type

• Alpha-blocker
• Phosphodiesterase Type-5 Inhibitors
• 5-alpha-Reductase Inhibitors

Global Benign Prostatic Hyperplasia Drugs Market :Application

• Hospitals
• Clinics

Global Benign Prostatic Hyperplasia Drugs Market: Competitive Analysis

Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Global Benign Prostatic Hyperplasia Drugs Market:

• Astellas Pharma
• Eli Lilly
• GlaxoSmithKline
• Sanofi
• ADC Therapeutics
• Bayer HealthCare
• Bristol-Myers Squibb
• Valeant Pharmaceuticals
• Endo Pharmaceuticals
• Foresee Pharmaceuticals
• Madrigal Pharmaceuticals
• Merck
• Novartis
• Spectrum Pharmaceuticals
• Takeda Pharmaceuticals
• Teva
• Advaxis
• ANI Pharmaceuticals
• BHR Pharma

Geographical analysis ofGlobal Benign Prostatic Hyperplasia Drugs Market:

• North America
  • U.S.A
  • Canada
• Europe
  • France
  • Germany
  • Spain
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South East Asia
• Latin America
  • Brazil
• Middle East and Africa

Global Benign Prostatic Hyperplasia Drugs Market Report delivers a comprehensive analysis of the following parameters:

• Market Forecast for 2024-2030
• Market growth drivers
• Challenges and Opportunities
• Emerging and Current market trends
• Market player Capacity, Production, Revenue (Value)
• Supply (Production), Consumption, Export, Import analysis
• End user/application Analysis

---

Frequently Asked Questions (FAQ)